Information  X 
Enter a valid email address

Futura Medical PLC (FUM)

  Print      Mail a friend       Annual reports

Thursday 30 May, 2019

Futura Medical PLC

Block listing Interim Review

RNS Number : 5327A
Futura Medical PLC
30 May 2019
 


 

 

                                                   

 

 

 

30 May 2019

 

 

Futura Medical plc (AIM: FUM)

("Futura" or "the Company")

 

Block Listing Update

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

The table below provides further detail.

 

Name of company:

Futura Medical plc



Name of scheme(s):

Unapproved Share Option Scheme ("USOS")

Unapproved Share Incentive Scheme  ("USIS")

EMI Share Option Scheme ("EMI")



Period of return:

From:

1 December 2018



To:

30 May 2019



 

Number and class of securities not issued under the scheme(s) at beginning of period

 

USOS:

 

1,993,875



USIS:

425,000



EMI:

3,806,125



Total:

6,225,000



Number and class of securities admitted to the scheme(s) in the period

USOS:

-



USIS:

-



EMI:

-



Total:

-



Number of securities issued under the scheme(s) during the period

USOS:

-



USIS:

-



EMI:

-



Total:

-



Number of securities lapsed under the scheme(s) during the period

USOS:

-



USIS:

-



EMI:

-



Total:

-



Balance of securities under the scheme(s) not yet issued at the end of the period

USOS:

1,993,875



USIS:

425,000



EMI:

3,806,125



Total:

6,225,000






 

 

Number and class of securities originally admitted and the date of admission

 

USOS:

 

814,424

25 May 2011,

1,202,280

8 October 2013,

1,466,208

25 May 2017,

400,000

30 May 2018,

 

USOS Total:

        3,882,912



 USIS:

425,000

30 November 2018

 

 

 

 


USIS Total:

425,000



EMI:

1,520,576

25 May 2011,

1,467,720

8 October 2013,

1,893,792

25 May 2017,

790,000

30 May 2018,

1,340,000

30 November 2018



EMI Total:

7,012,088







Total:

11,320,000











For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [email protected]
Tel: +44 (0) 1483 685 670

Liberum (Nominated Adviser and Broker)

Bidhi Bhoma
Euan Brown
Kane Collings
Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: [email protected]

Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRBRGDUSDDBGCC

a d v e r t i s e m e n t